The third quarter of 2024 saw a slight pickup in pace for FDA new drug approvals, with a total of 13 (Table 1) beating the 11 in Q2 and 10 in Q1. Interestingly though, the commercial expectations for the cohort of Q3 approvals is much greater than those from the first two quarters of the year. While forecasts are not available for all products, the Q3 cohort is anticipated to achieve sales of ~US$11.9 billion in 2030 according to Evaluate Pharma consensus forecasts at the time of writing, compared with $6.3 billion and $6.9 billion for the Q1 and Q2 cohorts, respectively.

Enjoying our latest content?
Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research
Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD